| Abstrakt: |
A recent study conducted by the SRM Institute of Science and Technology in Tamil Nadu, India, examined the trends in clinical trials among the BRICS nations (Brazil, Russia, India, China, and South Africa) over the past five years. The study found that these emerging economies have significantly increased their contributions to clinical research, reducing the gap with the G7 nations (Canada, France, Germany, Italy, Japan, the UK, the USA, and the European Union). China and the US had the highest number of trials among the BRICS and G7, respectively, with cancer being the most common indication for clinical trials in the BRICS. The study suggests that the strengths of the BRICS nations make them attractive destinations for investment in drug development. [Extracted from the article] |
